References
- National Psoriasis Foundation. About psoriasis. Accessed 15 November 2005. URL: http://www.psoriasis.org/about/stats/
- Unaeze J., Nijsten T., Murphy A., Ravichandran C., Stern R. S. Impact of psoriasis on health‐related quality of life decreases over time: An 11‐year prospective study. J Invest Dermatol 2006; 126: 1480–9
- Sander H. M., Morris L. F., Phillips C. M., Harrison P. E., Menter A. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28: 422–5
- Tristani‐Firouzi P., Krueger G. G. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61: 11–21
- Finlay A. Y., Ortonne J. P. Patient satisfaction with psoriasis therapies: An update and introduction to biologic therapy. J Cutan Med Surg 2004; 8: 310–20
- Camisa C. Psoriasis: A clinical update on diagnosis and new therapies. Cleve Clin J Med 2000; 67: 105–13
- National Psoriasis Foundation. NPF Benchmark survey on psoriasis and psoriatic arthritis. Accessed 24 April 2006. URL: http://www.psoriasis.org/files/pdfs/press/npfsurvey.pdf
- Weinberg J. M. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25: 2487–505
- Pearce D. J., Boles A., Greist H. M., Feldman S. R. Biologic therapy for psoriasis: Telephone triage. Dermatol Nurs 2005; 17: 265–70
- Balkrishnan R. The importance of medication adherence in improving chronic‐disease related outcomes: What we know and what we need to further know. Med Care 2005; 43: 517–20
- Stein K. R., Pearce D. J., Feldman S. R. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005; 24: 52–7
- Rich S. J. Considerations for assessing the cost of biologic agents in the treatment of psoriasis. J Manag Care Pharm 2004; 10: S38–41
- Centers for Medicare and Medicaid services. Table of contents for the state of NC. Accessed 24 April 2006. URL: http://www.cms.hhs.gov/medicaid/stateplans/toc.asp?state = NC
- Steiner J. F., Koepsell T. D., Fihn S. D., Inui T. S. A general method of compliance assessment using centralized pharmacy records. Med Care 1988; 26: 814–23
- Charlson M. E., Pompei P., Ales K. L., MacKenzie C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40: 373–83
- Deyo R. A., Cherkin D. C., Ciol M. A. Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. J Clin Epidemiol 1992; 45: 613
- Kennedy P. Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Econ Rev 1981; 71: 801
- Halvorsen R., Palmquist R. The interpretation of dummy variables in semilogarithmic equations. Am Econ Rev 1980; 70: 474
- Greene W. H. Econometric analysis. 3. Prentice Hall, Upper Saddle River, NJ 1997
- Breusch T. S., Pagan A. R. The Lagrange multiplier test and its application to model specification in econometrics. Rev Econ Stud 1980; 47: 239–53
- Hausman J. A. Specification tests in econometrics. Econometrica 1978; 46: 1251–71
- Winkelmann R. Econometric analysis of count data. 4. 2003, Springer‐Verlag, Berlin
- Krueger G. G., Papp K. A., Stough D. B., Loven K. H., Gulliver W. P., Ellis C. N., et al. A randomized, double‐blind, placebo‐controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821–33
- Menter A., Gather J. C. Long‐term use of intravenous alefacept: safety and off‐treatment responses in patients who have received four or more courses of therapy [abstract P588]. J Am Acad Dermatol 2004; 50: 151
- Gordon K. B., Papp K. A., Hamilton T. K., Walicke P. A., Dummer W., Li N., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073–80